Welcome to our dedicated page for WEST PHARMACEUTICAL SERVICES SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on WEST PHARMACEUTICAL SERVICES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into WEST PHARMACEUTICAL SERVICES's regulatory disclosures and financial reporting.
West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported equity award activity involving restricted stock units and common shares. On February 20, 2026, 60.220 restricted stock units converted into 60.220 shares of common stock on a one-for-one basis, increasing his directly held common shares to 1,429.966.
To cover tax obligations related to the vesting, 22.069 common shares were disposed of at $241.12 per share through a tax-withholding transaction, leaving him with 1,407.897 directly owned common shares. After the transaction, he also directly held 177.644 restricted stock units, which can convert into common stock in the future under the award terms.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised restricted stock units into common stock and had shares withheld to cover taxes. On February 20, 2026, he converted 89.328 restricted stock units into the same number of common shares at $0.00 per share, increasing his direct common stock holdings to 1,552.994 shares. On the same date, 30.184 common shares were disposed of at $241.12 per share in a tax-withholding transaction, leaving him with 1,522.810 common shares directly owned. Footnotes state these restricted stock units convert to common stock on a one-for-one basis and relate to a prior grant that vests in four equal annual installments.
West Pharmaceutical Services senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares. He acquired 82.299 common shares through the exercise or conversion of restricted stock units, which convert into common stock on a one-for-one basis.
Following this conversion, 27.809 common shares were disposed of at 248.26 per share to cover tax obligations through a tax-withholding disposition, rather than an open-market sale. After these transactions, his direct common stock holdings totaled 307.398 shares, and he held 247.899 restricted stock units directly. A prior grant of 329 restricted stock units vests in four equal annual installments, including dividend equivalents.
West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported two stock transactions in company common stock. He acquired 115.910 shares at a stated price of $0.0000, representing shares issued from performance stock units that vested for the 2023–2025 performance period.
On the same date, 41.519 shares were disposed of at $243.1900 per share to cover tax obligations through share withholding, rather than an open-market sale. After these transactions, he directly owned 1,369.746 shares of West Pharmaceutical Services common stock.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters reported equity-related transactions involving company common stock. On February 17, 2026, he acquired 149.684 shares at a price of $0.00 per share as a grant or award. A footnote explains these shares resulted from performance stock units for the 2023–2025 performance period that vested and became payable on that date.
On the same date, Winters disposed of 50.579 shares at $243.19 per share to cover tax liabilities through share withholding, rather than an open-market sale. After these transactions, he directly owned 1,462.103 common shares.
West Pharmaceutical Services President and CEO Eric Mark Green reported several equity-related transactions. On February 17, 2026, he acquired 4,418.771 shares of common stock as a grant. On February 18, 2026, 1,318.810 restricted stock units, stemming from 2023–2025 performance stock units, converted into common stock on a one-for-one basis. To cover tax obligations, he disposed of 1,305.382 shares at $243.19 and 573.551 shares at $248.26. Following these transactions, he directly owned 175,160.6588 common shares and indirectly held 257.375 shares through a Non-Qualified Deferred Compensation Plan.
West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite reported multiple equity transactions. On February 17, 2026, she acquired 441.957 shares of common stock through a grant or award and had 150.443 shares withheld to cover tax obligations. On February 18, 2026, she exercised 135.491 restricted stock units, converting them into the same number of common shares, with 35.757 shares withheld for taxes at prices of $243.1900 and $248.2600 per share, respectively. After these direct transactions, she held 17,374.4904 common shares directly and 4,962.0000 shares indirectly through a Non-Qualified Deferred Compensation Plan. Footnotes state that performance stock units from the 2023-2025 period vested and that restricted stock units convert into common stock on a one-for-one basis.
West Pharmaceutical Services, Inc. filed its annual report detailing a global injectable drug-packaging and delivery business organized into Proprietary Products and Contract-Manufactured Products. Sales outside the U.S. represented 56.7% of 2025 consolidated net sales, underscoring its international exposure.
The company highlights concentration risk: its ten largest customers made up 47.6% of 2025 net sales, and one customer contributed 15.8% or $485.9 million. As of June 30, 2025, non‑affiliate market value was about $15.7 billion, and there were 72,021,491 shares outstanding on January 29, 2026.
West employed about 10,800 people as of December 31, 2025 and continued quarterly dividends, raising the payout to $0.22 per share in the fourth quarter of 2025. The filing discusses supply chain, inflation, GLP‑1 exposure, cybersecurity, climate and regulatory risks, and notes a definitive agreement to sell the SmartDose 3.5mL On‑Body Delivery System rights and facilities to AbbVie.
West Pharmaceutical Services SVP & CFO Robert W. McMahon reported equity award activity on February 11, 2026. He converted 4,230.525 restricted stock units into the same number of common shares at an exercise price of $0.
To cover tax obligations, 1,250.034 common shares were withheld at $246.16 per share, leaving 2,980.491 common shares held directly after the transaction. He also reported 8,462.052 restricted stock units remaining outstanding following these events.
West Pharmaceutical Services, Inc. reported steady growth for the fourth quarter and full year 2025 and issued 2026 guidance. Fourth-quarter net sales were $805.0 million, up 7.5% with 3.3% organic growth, and adjusted diluted EPS rose 12.1% to $2.04.
For 2025, net sales reached $3.074 billion, increasing 6.3% with 4.3% organic growth, while adjusted diluted EPS grew 8.0% to $7.29. Operating cash flow was $754.8 million and free cash flow rose 69.6% to $468.9 million, reflecting lower capital spending.
Management expects 2026 net sales between $3.215 billion and $3.275 billion, implying 5% to 7% organic growth, and adjusted diluted EPS between $7.85 and $8.20, or 7.7% to 12.5% growth. Guidance assumes a mid-2026 close for the SmartDose 3.5mL sale to AbbVie.